232 related articles for article (PubMed ID: 22697346)
41. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis.
Kälin N; Claass A; Sommer M; Puchelle E; Tümmler B
J Clin Invest; 1999 May; 103(10):1379-89. PubMed ID: 10330420
[TBL] [Abstract][Full Text] [Related]
42. The ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Is Associated With Progressive Insulin Resistance and Decreased Functional β-Cell Mass in Mice.
Fontés G; Ghislain J; Benterki I; Zarrouki B; Trudel D; Berthiaume Y; Poitout V
Diabetes; 2015 Dec; 64(12):4112-22. PubMed ID: 26283735
[TBL] [Abstract][Full Text] [Related]
43. Loss of Cftr function exacerbates the phenotype of Na(+) hyperabsorption in murine airways.
Livraghi-Butrico A; Kelly EJ; Wilkinson KJ; Rogers TD; Gilmore RC; Harkema JR; Randell SH; Boucher RC; O'Neal WK; Grubb BR
Am J Physiol Lung Cell Mol Physiol; 2013 Apr; 304(7):L469-80. PubMed ID: 23377346
[TBL] [Abstract][Full Text] [Related]
44. The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain.
Hoelen H; Kleizen B; Schmidt A; Richardson J; Charitou P; Thomas PJ; Braakman I
PLoS One; 2010 Nov; 5(11):e15458. PubMed ID: 21152102
[TBL] [Abstract][Full Text] [Related]
45. Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease.
Ko YH; Pedersen PL
J Bioenerg Biomembr; 2001 Dec; 33(6):513-21. PubMed ID: 11804193
[TBL] [Abstract][Full Text] [Related]
46. Mild processing defect of porcine DeltaF508-CFTR suggests that DeltaF508 pigs may not develop cystic fibrosis disease.
Liu Y; Wang Y; Jiang Y; Zhu N; Liang H; Xu L; Feng X; Yang H; Ma T
Biochem Biophys Res Commun; 2008 Aug; 373(1):113-8. PubMed ID: 18555011
[TBL] [Abstract][Full Text] [Related]
47. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments.
Sharma M; Benharouga M; Hu W; Lukacs GL
J Biol Chem; 2001 Mar; 276(12):8942-50. PubMed ID: 11124952
[TBL] [Abstract][Full Text] [Related]
48. FK506 binding protein 8 peptidylprolyl isomerase activity manages a late stage of cystic fibrosis transmembrane conductance regulator (CFTR) folding and stability.
Hutt DM; Roth DM; Chalfant MA; Youker RT; Matteson J; Brodsky JL; Balch WE
J Biol Chem; 2012 Jun; 287(26):21914-25. PubMed ID: 22474283
[TBL] [Abstract][Full Text] [Related]
49. Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue.
Hodos RA; Strub MD; Ramachandran S; Li L; McCray PB; Dudley JT
Sci Rep; 2020 Nov; 10(1):20553. PubMed ID: 33239626
[TBL] [Abstract][Full Text] [Related]
50. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
Wang F; Zeltwanger S; Hu S; Hwang TC
J Physiol; 2000 May; 524 Pt 3(Pt 3):637-48. PubMed ID: 10790148
[TBL] [Abstract][Full Text] [Related]
51. Annexin A5 increases the cell surface expression and the chloride channel function of the DeltaF508-cystic fibrosis transmembrane regulator.
Le Drévo MA; Benz N; Kerbiriou M; Giroux-Metges MA; Pennec JP; Trouvé P; Férec C
Biochim Biophys Acta; 2008 Oct; 1782(10):605-14. PubMed ID: 18773956
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic approaches to CFTR dysfunction: From discovery to drug development.
Li H; Pesce E; Sheppard DN; Singh AK; Pedemonte N
J Cyst Fibros; 2018 Mar; 17(2S):S14-S21. PubMed ID: 28916430
[TBL] [Abstract][Full Text] [Related]
53. The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.
Bodas M; Vij N
Discov Med; 2010 Apr; 9(47):346-56. PubMed ID: 20423679
[TBL] [Abstract][Full Text] [Related]
54. Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines.
Park J; Khloya P; Seo Y; Kumar S; Lee HK; Jeon DK; Jo S; Sharma PK; Namkung W
PLoS One; 2016; 11(2):e0149131. PubMed ID: 26863533
[TBL] [Abstract][Full Text] [Related]
55. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis.
Bergougnoux A; Petit A; Knabe L; Bribes E; Chiron R; De Sario A; Claustres M; Molinari N; Vachier I; Taulan-Cadars M; Bourdin A
Int J Biochem Cell Biol; 2017 Jul; 88():124-132. PubMed ID: 28478266
[TBL] [Abstract][Full Text] [Related]
56. Novel Approaches for Potential Therapy of Cystic Fibrosis.
Sawczak V; Getsy P; Zaidi A; Sun F; Zaman K; Gaston B
Curr Drug Targets; 2015; 16(9):923-36. PubMed ID: 25557257
[TBL] [Abstract][Full Text] [Related]
57. Cytoskeleton and CFTR.
Edelman A
Int J Biochem Cell Biol; 2014 Jul; 52():68-72. PubMed ID: 24685681
[TBL] [Abstract][Full Text] [Related]
58. Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding.
Serohijos AW; Hegedus T; Riordan JR; Dokholyan NV
PLoS Comput Biol; 2008 Feb; 4(2):e1000008. PubMed ID: 18463704
[TBL] [Abstract][Full Text] [Related]
59. Functional cystic fibrosis transmembrane conductance regulator tagged with an epitope of the vesicular stomatis virus glycoprotein can be addressed to the apical domain of polarized cells.
Costa de Beauregard MA; Edelman A; Chesnoy-Marchais D; Tondelier D; Lapillonne A; El Marjou F; Robine S; Louvard D
Eur J Cell Biol; 2000 Nov; 79(11):795-802. PubMed ID: 11139142
[TBL] [Abstract][Full Text] [Related]
60. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis.
Reilly R; Mroz MS; Dempsey E; Wynne K; Keely SJ; McKone EF; Hiebel C; Behl C; Coppinger JA
Sci Rep; 2017 Aug; 7(1):7642. PubMed ID: 28794469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
